Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

1(33%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

33%

Ph not_applicable

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 2Efficacy & side effects

1(33.3%)

N/ANon-phased studies

2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(1)

Other(1)

Detailed Status

unknown1

Recruiting1

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 21 (33.3%)

N/A2 (66.7%)

Trials by Status

unknown133%

recruiting133%

completed133%

Recent Activity

1 active trials

Showing 3 of 3

recruitingphase_2

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

NCT06906562

completednot_applicable

Triamcinolone Acetonide in Patients With Serous Pigment Epithelial Detachment

NCT04292756

unknownnot_applicable

Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Central Chorioretinitis

NCT04245072

Clinical Trials (3)

Showing 3 of 3 trials

NCT06906562Phase 2

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

Recruiting

NCT04292756Not Applicable

Triamcinolone Acetonide in Patients With Serous Pigment Epithelial Detachment

Completed

NCT04245072Not Applicable

Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Central Chorioretinitis

Unknown

All 3 trials loaded

Drug Details

Intervention Type: PROCEDURE
Total Trials: 3